Bajaj Healthcare Limited has reported a standalone net loss of ₹22.85 crore for the fourth quarter ended March 31, 2026. This performance stands in sharp contrast to the net profit of ₹11.17 crore recorded during the same period in the previous fiscal year. The company’s revenue from operations saw a marginal decline of 0.91%, settling at ₹153.05 crore compared to ₹154.47 crore in Q4 FY25.
The pharmaceutical major faced a challenging operating environment characterized by significant price erosion in the domestic Active Pharmaceutical Ingredients (API) segment and the early economic impacts of geopolitical tensions in West Asia. These external factors contributed to a pre-tax loss of ₹20.80 crore for the quarter. Segment-wise performance was mixed; while domestic API revenue fell by 2.56% and API exports declined by 5.42%, the formulations business provided a silver lining, surging 27.67% to reach ₹27.67 crore.
Despite the bottom-line pressure, Bajaj Healthcare reported some operational resilience. The EBITDA margin saw a slight improvement, rising to 16.7% from 16.4% a year ago. Managing Director Anil Jain noted that while revenue remained stable despite high volume growth, the company maintained a strong focus on cost management and operational discipline. For the full fiscal year 2026, the company achieved a 12.6% revenue growth, bolstered by a remarkable 51.6% increase in API exports to regulated markets such as the EU, UK, and LATAM.
Looking ahead, the company is betting heavily on its research and development pipeline to drive future value. Its novel anti-epileptic molecule, Cenobamate, is currently in Phase III clinical trials and is on schedule for a Q2 FY27 launch. This move is expected to significantly strengthen the company’s footprint in the Central Nervous System (CNS) therapeutics market. Additionally, the company has completed bioequivalence studies for Suvorexant tablets and plans to file with the DCGI shortly.
Bajaj Healthcare also made significant strides on the regulatory and financial fronts during the quarter. The company filed 41 Drug Master Files (DMFs), bringing its total global filings to 110. Furthermore, it successfully raised ₹52.7 crore through the conversion of 2.08 million warrants into equity shares. This fresh capital infusion is earmarked to strengthen the balance sheet and fund upcoming growth initiatives. While the fourth quarter was marked by volatility, the company’s management remains optimistic that its focus on high-value regulated markets and advanced drug molecules will facilitate a steady recovery in the coming fiscal years.
